CAMP insider transaction filings
Camp4 Therapeutics Corp — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-02. Screen CAMP transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 11 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 5 filings by 4 insiders — 46,031 shares, $99,051 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 6 legs across 4 filings by 2 insiders — 593,613 shares, $2,504,037 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: sale of 400,000 shares @ $4.04 ($1,616,000) by Schwab Andrew J., filed 2026-08-31.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Schwab Andrew J. — Director | 4 | — | 5 legs · 591,875 sh · $2,495,764 | 1 |
| Gold Kelly — Chief Financial Officer | 2 | 2 legs · 16,551 sh · $50,409 | — | — |
| Young Richard A — Director | 1 | 1 leg · 16,378 sh · $27,024 | — | — |
| Mandel-Brehm Josh — Chief Executive Officer, Director | 1 | 1 leg · 6,551 sh · $10,809 | — | — |
| Maricich Yuri — Chief Medical Officer | 1 | 1 leg · 6,551 sh · $10,809 | — | — |
| Tardiff Daniel — Chief Scientific Officer | 1 | — | 1 leg · 1,738 sh · $8,273 | — |
| 5AM Partners VI, LLC — 10% owner & 5AM Ventures VI, L.P. — 10% owner & 5AM Opportunities II (GP), LLC — 10% owner & 5AM Opportunities II, L.P. — 10% owner & 5AM Partners VII, LLC — 10% owner & 5AM Ventures VII, L.P. — 10% owner & PARMAR KUSH — 10% owner | 1 | — | — | 1 |
Recent Form 4 filings — Camp4 Therapeutics Corp
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Gold Kelly — Chief Financial Officer | Purchase (P): 10,000 @ $3.96 | EDGAR |
| 2026-08-31 | 4 | Schwab Andrew J. — Director | Sale (S): 400,000 @ $4.04 | EDGAR |
| 2026-08-26 | 4 | Schwab Andrew J. — Director | Sale (S): 10 @ $4.50 | EDGAR |
| 2026-08-21 | 4 | Schwab Andrew J. — Director | Sale (S): 45,147 @ $4.76 · Sale (S): 114,700 @ $4.54 · Sale (S): 32,018 @ $4.50 | EDGAR |
| 2026-08-19 | 4 | Tardiff Daniel — Chief Scientific Officer | Sale (S): 1,738 @ $4.76 | EDGAR |
| 2026-08-05 | 4 | 5AM Partners VI, LLC — 10% owner 5AM Ventures VI, L.P. — 10% owner 5AM Opportunities II (GP), LLC — 10% owner 5AM Opportunities II, L.P. — 10% owner 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner PARMAR KUSH — 10% owner | Purchase (P): 3,179,558 (derivative) @ $1.53 | EDGAR |
| 2026-08-05 | 4 | Schwab Andrew J. — Director | Grant/award (A): 3,179,558 (derivative) @ $1.53 | EDGAR |
| 2026-08-05 | 4 | Maricich Yuri — Chief Medical Officer | Purchase (P): 6,551 @ $1.65 | EDGAR |
| 2026-08-05 | 4 | Young Richard A — Director | Purchase (P): 16,378 @ $1.65 | EDGAR |
| 2026-08-05 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Purchase (P): 6,551 @ $1.65 | EDGAR |
| 2026-08-05 | 4 | Gold Kelly — Chief Financial Officer | Purchase (P): 6,551 @ $1.65 | EDGAR |
| 2026-06-12 | 4 | Stewart Murray — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Schwab Andrew J. — Director, 10% owner | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Nashat Amir — Director, 10% owner | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Young Richard A — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Holtzman Steven H — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | WILLIAMS DOUGLAS E — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Tardiff Daniel — Chief Scientific Officer | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Gold Kelly — Chief Financial Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Grant/award (A): 580,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Maricich Yuri — Chief Medical Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | MacLean Michael F — Director | Grant/award (A): 56,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Tardiff Daniel — Chief Scientific Officer | Grant/award (A): 145,500 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Gold Kelly — Chief Financial Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Grant/award (A): 425,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Maricich Yuri — Chief Medical Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2025-09-15 | 4 | 5AM Partners VI, LLC — 10% owner 5AM Ventures VI, L.P. — 10% owner 5AM Opportunities II (GP), LLC — 10% owner 5AM Opportunities II, L.P. — 10% owner 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner PARMAR KUSH — 10% owner | Purchase (P): 2,941,176 @ $1.53 | EDGAR |
| 2025-09-15 | 4 | Schwab Andrew J. — Director, 10% owner | Grant/award (A): 2,941,176 @ $1.53 | EDGAR |
| 2025-09-11 | 4 | Gold Kelly — Chief Financial Officer | Purchase (P): 6,060 @ $1.65 | EDGAR |
| 2025-09-11 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Purchase (P): 6,060 @ $1.65 | EDGAR |
| 2025-09-11 | 4 | Maricich Yuri — Chief Medical Officer | Purchase (P): 6,060 @ $1.65 | EDGAR |
| 2025-09-11 | 4 | Nashat Amir — Director, 10% owner | Purchase (P): 1,221,721 @ $1.53 · Purchase (P): 85,468 @ $1.53 | EDGAR |
| 2025-09-11 | 4 | Young Richard A — Director | Purchase (P): 15,151 @ $1.65 | EDGAR |
| 2025-09-11 | 4 | Polaris Management Co. VII, L.L.C. — 10% owner Polaris Partners VII, L.P. — 10% owner Polaris Entrepreneurs' Fund VII, L.P. — 10% owner Polaris Partners X, L.P. — 10% owner Polaris Partners GP X, L.L.C. — 10% owner SCHULMAN AMY W — 10% owner Chee Brian — 10% owner | Purchase (P): 1,221,721 @ $1.53 · Purchase (P): 85,468 @ $1.53 | EDGAR |
| 2025-06-27 | 4 | Boylan James P — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Thadhani Ravi I. — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Ragan Paula — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Schwab Andrew J. — Director, 10% owner | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Nashat Amir — Director, 10% owner | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Young Richard A — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Higgins Michael J — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Holtzman Steven H — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Bumcrot David — Chief Scientific Officer | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Maricich Yuri — Chief Medical Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Gold Kelly — Chief Financial Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | Stewart Murray — Director | Grant/award (A): 17,787 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | WILLIAMS DOUGLAS E — Director | Grant/award (A): 17,787 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4/A | Polaris Management Co. VII, L.L.C. — 10% owner Polaris Partners VII, L.P. — 10% owner Polaris Entrepreneurs' Fund VII, L.P. — 10% owner Polaris Partners X, L.P. — 10% owner Polaris Partners GP X, L.L.C. — 10% owner SCHULMAN AMY W — 10% owner Chee Brian — 10% owner | Conversion (C): 1,250,061 · Conversion (C): 87,448 · Conversion (C): 353,718 · Conversion (C): 24,745 · Purchase (P): 909,090 @ $11 · Conversion (C): 14,020,475 (derivative) · +3 more | EDGAR |
| 2024-10-17 | 4 | AH Equity Partners Bio I, L.L.C. — 10% owner AH Bio Fund I, L.P. — 10% owner AH Equity Partners Bio IV, L.L.C. — 10% owner AH Bio Fund IV, L.P. — 10% owner Andreessen Marc L — 10% owner HOROWITZ BENJAMIN A — 10% owner | Conversion (C): 1,398,067 · Purchase (P): 181,818 @ $11 · Purchase (P): 545,454 @ $11 · Conversion (C): 15,001,312 (derivative) · Conversion (C): 679,163 (derivative) | EDGAR |
Recent 8-K events — Camp4 Therapeutics Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-05 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CAMP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →